Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 4/20 | 0.57 |
| ▸ | APLNR | P35414 | 1/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7002432 | 0.84 | APLNR (0.73) | APLNRHTR2AHTR2CHDAC3HDAC1 | |
| SCHEMBL3265286 | 0.83 | SLC2A1 (0.81) | SLC2A1GRIN1GRIN2ACHRM2 | |
| SCHEMBL17138360 | 0.80 | APLNR (0.71) | APLNRHTR2AHTR2CGRIN1GRIN2A | |
| SCHEMBL3264888 | 0.79 | APLNR (0.50) | SLC2A1APLNRKDM1AMAOAHTR2A | |
| SCHEMBL3266399 | 0.77 | APLNR (0.49) | SLC2A1APLNRKDM1AMAOAHTR2A | |
| SCHEMBL18256578 | 0.75 | APLNR (0.77) | APLNRHTR2AHTR2CKDM4EALDH1A1 | |
| SCHEMBL18182124 | 0.75 | HTR2A (0.62) | APLNRHTR2AHTR2CALDH1A1HDAC3 | |
| SCHEMBL13263310 | 0.74 | KDM1A (0.63) | APLNRKDM1AMAOAKDM4EALDH1A1 | |
| SCHEMBL8852020 | 0.74 | SLC2A1 (0.75) | SLC2A1KDM1AMAOAGRIN1GRIN2A | |
| SCHEMBL15780142 | 0.73 | ADRA1A (0.53) | APLNRKDM1AMAOAHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004262-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | ORYZON GENOMICS, S.A. (ES) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004262-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | PNMT, ABCB1, SNCA | SLC2A1 1019/4885APLNR 1155/4885KDM1A 1515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.